Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,496.00-0.54%ETH$2,695.79-0.76%GOLD$4,194.70+0.18%OIL$89.85+0.46%
Smart Investors Daily
SID Premium
Beta Bionics, Inc. logo

NASDAQ · BBNX

Beta Bionics, Inc.

Healthcare · Medical - Equipment & Services

$18.95

Down-$0.32 (-1.69%)

Updated Oct 6, 2026, 8:04 PM

SID Score

4.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.29B
P/E ratio
-16.44
Dividend yield
0.00%
52-week range
$8.80 – $32.71
Volume
624.63K
Avg. volume
804.67K

Price performance · BBNX

BBNX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

BBNX closed at $18.95 after 20 trading sessions, down 1.97% for the selected period.

Last close
$18.95
Period change
-1.97%
Period low
$16.57
Period high
$22.81
Daily close
View OHLC price history
BBNX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$18.91$19.265$18.735$18.95624.63K
Oct 2, 2026$18.87$19.26$18.27$18.96515.08K
Oct 1, 2026$19.35$19.44$18.39$18.871.14M
Sep 30, 2026$19.22$19.52$18.45$18.981.46M
Sep 29, 2026$20.61$20.725$19.28$19.41842.61K
Sep 28, 2026$21.50$21.695$19.93$20.521.76M
Sep 25, 2026$21.74$21.98$21.25$21.51926.01K
Sep 24, 2026$22.31$22.62$21.44$21.76906.85K
Sep 23, 2026$23.00$23.4804$21.88$22.191.4M
Sep 22, 2026$22.18$23.56$22.10$22.81999.59K
Sep 21, 2026$22.11$22.48$21.78$22.04783.3K
Sep 18, 2026$21.30$22.1558$21.10$21.891.53M
Sep 17, 2026$22.46$22.66$20.39$21.433.09M
Sep 16, 2026$18.61$22.22$18.40$22.187.19M
Sep 15, 2026$16.73$19.55$16.37$19.231.7M
Sep 14, 2026$15.52$17.60$15.51$16.731.81M
Sep 11, 2026$16.585$16.71$15.845$16.57726.15K
Sep 10, 2026$17.60$17.9517$16.4962$16.59957.71K
Sep 9, 2026$19.14$19.54$17.258$17.42848.75K
Sep 8, 2026$19.18$19.52$18.75$19.33900.83K

Latest BBNX news

The latest Smart Investors Daily articles mentioning BBNX.

Stock researchCompany · Overview

BBNX research

Overview

Company profile and research snapshot.

Company profile

Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$31.00
Implied upside
—
Analysts
16
BBNX recent ratings
DateFirmRatingTarget
Sep 24, 2026Truist SecuritiesBuy—
Sep 23, 2026Wells FargoOverweight—
Sep 15, 2026Truist SecuritiesBuy—
Sep 15, 2026B of A SecuritiesNeutral—
Sep 15, 2026BairdNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 29, 2026

Beta Bionics to Announce Third Quarter 2026 Financial Results on October 27, 2026

IRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its third quarter 2026 financial results after the financial markets close on Tuesday, October 27, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company’s third quarter 2026 performance. The

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By